From: Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial
Fractions (n)
Total prescribed dose (Gy)
Clinical goal
Minor variation
2
24
•PTV V100% > 95%
•PTV V95% ≥ 99%
•PTV V100% > 90%
•PTV V92% ≥ 99%
3
30
5
35